FDA Approves EMGALITY — Eli Lilly and Company
On September 27, 2018, Eli Lilly and Company received FDA approval for the brand-name treatment EMGALITY (galcanezumab-gnlm), a structural analog of galcanezumab intended for the acute treatment of migraine. This approval bolsters Eli Lilly’s portfolio in the neurology space by expanding its headache therapies, potentially strengthening its competitiveness against similar anti-CGRP agents in the burgeoning migraine prevention market.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed